Cian Healthcare Ltd
Incorporated in 2003, Cian Healthcare Ltd is engaged in manufacturing and marketing of pharmaceutical products.[1]
- Market Cap ₹ 12.5 Cr.
- Current Price ₹ 5.01
- High / Low ₹ 7.66 / 2.99
- Stock P/E
- Book Value ₹ 13.0
- Dividend Yield 0.00 %
- ROCE -10.6 %
- ROE -30.3 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.39 times its book value
- Promoter holding has increased by 67.9% over last quarter.
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -11.6% over past five years.
- Company has a low return on equity of -6.85% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 206 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 57 | 74 | 78 | 69 | 62 | 31 | |
| 50 | 62 | 74 | 56 | 51 | 37 | |
| Operating Profit | 7 | 12 | 4 | 13 | 11 | -7 |
| OPM % | 13% | 16% | 6% | 19% | 18% | -21% |
| 1 | 0 | 0 | 1 | 0 | -12 | |
| Interest | 7 | 8 | 7 | 6 | 6 | 3 |
| Depreciation | 4 | 3 | 4 | 5 | 5 | 4 |
| Profit before tax | -4 | 1 | -6 | 2 | 0 | -26 |
| Tax % | 7% | 91% | -8% | -2% | -1,600% | -0% |
| -4 | 0 | -6 | 2 | 1 | -26 | |
| EPS in Rs | -1.62 | 0.02 | -2.21 | 0.81 | 0.34 | -10.39 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -12% |
| 3 Years: | -27% |
| TTM: | -50% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -1716% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -15% |
| 3 Years: | -43% |
| 1 Year: | 50% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -6% |
| 3 Years: | -7% |
| Last Year: | -30% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 23 | 23 | 25 | 25 | 25 | 25 |
| Reserves | 35 | 35 | 30 | 32 | 33 | 7 |
| 73 | 70 | 63 | 61 | 56 | 55 | |
| 25 | 29 | 47 | 42 | 47 | 69 | |
| Total Liabilities | 157 | 157 | 166 | 160 | 161 | 156 |
| 39 | 37 | 50 | 45 | 39 | 35 | |
| CWIP | 25 | 26 | 13 | 14 | 15 | 15 |
| Investments | 5 | 5 | 5 | 5 | 5 | 5 |
| 87 | 90 | 98 | 97 | 102 | 101 | |
| Total Assets | 157 | 157 | 166 | 160 | 161 | 156 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| -7 | 6 | 9 | 5 | 12 | 21 | |
| -27 | 3 | 1 | 3 | -1 | -0 | |
| 36 | -10 | -11 | -7 | -10 | -4 | |
| Net Cash Flow | 1 | -1 | -1 | -0 | -0 | 17 |
| Free Cash Flow | -26 | 4 | 4 | 4 | 11 | 20 |
| CFO/OP | -99% | 49% | 197% | 37% | 106% | -315% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 128 | 94 | 125 | 140 | 121 | 206 |
| Inventory Days | 214 | 277 | 300 | 400 | 486 | 420 |
| Days Payable | 176 | 186 | 270 | 296 | 371 | 671 |
| Cash Conversion Cycle | 166 | 185 | 155 | 244 | 236 | -45 |
| Working Capital Days | 15 | 16 | 38 | 41 | 26 | -729 |
| ROCE % | 7% | 0% | 7% | 5% | -11% |
Insights
In beta| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Permanent Employees Number ・Standalone data |
|
||||||||
| Actual Production Volume - Capsules Lakhs Nos. ・Standalone data |
|||||||||
| Actual Production Volume - Tablets Lakhs Nos. ・Standalone data |
|||||||||
| Installed Capacity - Capsules Lakhs Nos. ・Standalone data |
|||||||||
| Installed Capacity - Tablets Lakhs Nos. ・Standalone data |
|||||||||
| Total Product Registrations Number ・Standalone data |
|||||||||
| Total Product Units Manufactured Units ・Standalone data |
|||||||||
| Export Registrations Pipeline Number ・Standalone data |
|||||||||
Documents
Announcements
-
Update On The Receipt Of The Trading Approval For The 2,50,00,000 (Two Crores Fifty Lakhs) Fully Paid-Up Equity Shares, At A Face Value Of INR 10/- (Indian Rupees Ten Only) Each, To The Public Shareholders And Promoters.
2d - BSE approved trading of 2,50,00,000 shares (12,50,000 public; 2,37,50,000 promoters), received March 30, 2026.
- Closure of Trading Window 26 Mar
-
Update On The Receipt Of The Listing Approval In Relation To The Issuance Of 2,37,50,000 (Two Crores Thirty-Seven Lakhs Fifty Thousand) Fully Paid-Up Equity Shares At A Face Value Of INR 10/- (Indian Rupees Ten Only) Each, To The Promoters.
21 Mar - BSE approved listing of 2,37,50,000 shares (INR23.75 crore) allotted to promoters under NCLT resolution.
- Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011 18 Mar
- Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011 18 Mar
Business Overview:[1][2]
CHI is a fully integrated pharmaceutical company dealing in gynecology, hematinic, cardio-diabetic, orthopedic, pediatric, derma-cosmetic, antibiotic, CNS, vitamins & nutrient products.